Study analysis · Cell reports · 2025
This common gym supplement might be the key to making cancer immunotherapy work better.
Creatine, the supplement athletes use, helps kill cancer cells and makes immune therapy work better in mice.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study was done in animals, not people, and we don't know how it was done well enough to trust the results. So we can't say creatine helps fight cancer in humans — it's just a guess based on a lab experiment.
What’s the bottom line?
This study found that creatine, a supplement often used by athletes, can trigger a type of cell death called ferroptosis in colorectal cancer cells by blocking a protein (ERK2) that normally protects cancer cells.
How strong is this study?
We don't know if the scientists did this study right because they didn't tell us enough. It's like reading a recipe with no ingredients or steps — you can't tell if the cake will turn out, so you shouldn't trust it yet.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 56 / 100
Probability of being correct
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
This design cannot establish causation — the findings describe an association, not a cause. Study design cannot be determined from abstract; randomization, blinding, and control group status are unknown. No evidence supports causal inference.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding information were disclosed in the provided text.
The study text contains no disclosure section, funding statement, author affiliations, or industry ties. Without additional information, no conflicts of interest can be identified.
Key takeaways
- 01
Creatine made tumors smaller, increased immune cells (CD8+ T cells) inside tumors, and helped anti-PD-1 immunotherapy work better in mice.
- 02
Yes — if this works in humans, taking creatine might help cancer patients respond better to immunotherapy drugs.
Surprising findings
- Creatine directly binds to ERK2 to inhibit its functionCreatine is known for energy storage in muscles — not as a direct molecular inhibitor of cancer signaling pathways.
Practical takeaways
Consider creatine supplementation if undergoing immunotherapy for colorectal cancer — but only under medical supervision.
This study was done in mice; human safety and effectiveness are unknown.
low confidenceWhy this study matters
Creatine Triggers Cancer Cell Death
Creatine binds to ERK2, blocking its activation by MEK1, which reduces phosphorylation and stabilization of FSP1 — a protein that protects cancer cells from ferroptosis. This leads to cancer cell death in colorectal cancer models.
It turns a popular supplement into a potential cancer-fighting tool by activating a specific type of cell death that tumors usually avoid.
Boosts Immune Cell Infiltration
Creatine supplementation increased CD8+ T cell infiltration into tumors in animal models, helping the immune system better target cancer cells.
It suggests creatine doesn’t just kill cancer cells directly — it also helps the body’s own immune system fight harder.
Makes Immunotherapy Work Better
Creatine supplementation sensitized colorectal tumors to anti-PD-1 immunotherapy in animal models, improving treatment response.
Immunotherapy doesn’t work for everyone — if creatine makes it work better, it could help thousands of patients who currently don’t respond.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study found that creatine, a supplement often used by athletes, can trigger a type of cell death called ferroptosis in colorectal cancer cells by blocking a protein (ERK2) that normally protects cancer cells.
Research results
Creatine made tumors smaller, increased immune cells (CD8+ T cells) inside tumors, and helped anti-PD-1 immunotherapy work better in mice.
What this means - more context
Yes — if this works in humans, taking creatine might help cancer patients respond better to immunotherapy drugs.
The study investigates whether creatine supplementation enhances cancer immunotherapy by modulating tumor metabolism and ferroptosis in colorectal cancer.
Creatine binds ERK2, inhibiting its activation by MEK1, which reduces phosphorylation and stabilization of FSP1, leading to ferroptosis in colorectal cancer cells. Creatine supplementation suppresses tumor growth, increases CD8+ T cell infiltration, and sensitizes tumors to anti-PD-1 immunotherapy in animal models.
Methods Used
Untargeted metabolomics was used; mechanistic insights were derived from experiments showing creatine binding to ERK2 and its downstream effects on FSP1 phosphorylation. SLC6A8 transporter inhibition was used to assess creatine uptake effects. No sample sizes, controls, or statistical methods are specified.
Main Finding
Creatine supplementation suppresses tumor growth, enhances CD8+ T cell infiltration, and sensitizes colorectal tumors to anti-PD-1 immunotherapy in animal models by inducing ferroptosis via ERK2-FSP1 pathway inhibition.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •No sample sizes, statistical measures, or control details provided
- •Animal study only — human relevance unknown
Surprising Findings
Creatine directly binds to ERK2 to inhibit its function
Creatine is known for energy storage in muscles — not as a direct molecular inhibitor of cancer signaling pathways.
Practical Takeaways
Consider creatine supplementation if undergoing immunotherapy for colorectal cancer — but only under medical supervision.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 56 / 100
Probability of being correct
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
Animal Case-Control
Subject
Lower probability
on the GRADE evidence scale
This study was done in animals, not people, and we don't know how it was done well enough to trust the results. So we can't say creatine helps fight cancer in humans — it's just a guess based on a lab experiment.
No conflicts of interest were detected in this study. No score impact.
Weaknesses
- Full methodology not available - based on abstract only
- Randomization status unknown
- Blinding status unknown
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study found that creatine, a supplement often used by athletes, can trigger a type of cell death called ferroptosis in colorectal cancer cells by blocking a protein (ERK2) that normally protects cancer cells.
Research results
Creatine made tumors smaller, increased immune cells (CD8+ T cells) inside tumors, and helped anti-PD-1 immunotherapy work better in mice.
What this means - more context
Yes — if this works in humans, taking creatine might help cancer patients respond better to immunotherapy drugs.
The study investigates whether creatine supplementation enhances cancer immunotherapy by modulating tumor metabolism and ferroptosis in colorectal cancer.
Creatine binds ERK2, inhibiting its activation by MEK1, which reduces phosphorylation and stabilization of FSP1, leading to ferroptosis in colorectal cancer cells. Creatine supplementation suppresses tumor growth, increases CD8+ T cell infiltration, and sensitizes tumors to anti-PD-1 immunotherapy in animal models.
Methods Used
Untargeted metabolomics was used; mechanistic insights were derived from experiments showing creatine binding to ERK2 and its downstream effects on FSP1 phosphorylation. SLC6A8 transporter inhibition was used to assess creatine uptake effects. No sample sizes, controls, or statistical methods are specified.
Main Finding
Creatine supplementation suppresses tumor growth, enhances CD8+ T cell infiltration, and sensitizes colorectal tumors to anti-PD-1 immunotherapy in animal models by inducing ferroptosis via ERK2-FSP1 pathway inhibition.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •No sample sizes, statistical measures, or control details provided
- •Animal study only — human relevance unknown
Surprising Findings
Creatine directly binds to ERK2 to inhibit its function
Creatine is known for energy storage in muscles — not as a direct molecular inhibitor of cancer signaling pathways.
Practical Takeaways
Consider creatine supplementation if undergoing immunotherapy for colorectal cancer — but only under medical supervision.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 56 / 100
Probability of being correct
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
Animal Case-Control
Subject
Lower probability
on the GRADE evidence scale
This study was done in animals, not people, and we don't know how it was done well enough to trust the results. So we can't say creatine helps fight cancer in humans — it's just a guess based on a lab experiment.
No conflicts of interest were detected in this study. No score impact.
Weaknesses
- Full methodology not available - based on abstract only
- Randomization status unknown
- Blinding status unknown
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
We don't know if the scientists did this study right because they didn't tell us enough. It's like reading a recipe with no ingredients or steps — you can't tell if the cake will turn out, so you shouldn't trust it yet.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 56 / 100
Probability of being correct
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
This design cannot establish causation — the findings describe an association, not a cause. Study design cannot be determined from abstract; randomization, blinding, and control group status are unknown. No evidence supports causal inference.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding information were disclosed in the provided text.
The study text contains no disclosure section, funding statement, author affiliations, or industry ties. Without additional information, no conflicts of interest can be identified.